Asset
TOBEVIBART
VIR BIOTECHNOLOGY INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05612581 | phase1_2 | completed | 2023-05-10 | 2024-10-15 | Vir Biotechnology, Inc. | A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection |
| NCT06903338 | phase3 | active_not_recruiting | 2025-03-12 | 2026-12-31 | Vir Biotechnology, Inc. | A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection |
| NCT07142811 | phase2 | active_not_recruiting | 2025-08-05 | 2026-11-01 | Vir Biotechnology, Inc. | A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection |
| NCT07128550 | phase3 | active_not_recruiting | 2025-07-30 | 2026-12-01 | Vir Biotechnology, Inc. | A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide |
| NCT05484206 | phase1 | completed | 2022-09-21 | 2025-12-09 | Vir Biotechnology, Inc. | Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 |
FDA applications (0)
This company has no applications containing this asset.